Rajiv M.

Led a remarkable turnaround and growth period, increasing the company's Revenue from INR 750M to over INR 4000M between 2016-2024, representing a 23% CAGR and maintaining EBITDA above 40%. Identified and executed multiple strategic acquisitions (2020, 2021, 2022) to expand the company's capabilities in API CDMO, GMP testing, In-vivo and Discovery services. Successfully managed the divestment of the company from the Tata Group to Eurofins, closing the transaction within 3 months and achieving a valuation acceptable to both parties. Orchestrated the strategic closure of a non-performing drug discovery unit, mitigating statutory risks and managing all related sensitivities, while refocusing the business on its core CRO services. Successfully steered the company through the global COVID-19 pandemic, exceeding annual targets for both 2020 and 2021.

Spearheaded the regulated market commercialization of the biosimilars portfolio. Led and closed multiple, complex strategic transactions with global partners including Teva, Mylan, Roche, and Novartis, securing licenses, acquisitions of ANDAs, and patent-related settlements. Successfully guided the greenfield setup of MENA operations for the company's subsidiary, Accord. Played a key role in the top-level team responsible for evaluating and implementing the company's acquisition strategy.

Led, negotiations and closed multiple drug discovery alliances with major global players—Takeda, Merck, Novartis and Janssen. Raised $18 million in equity funding for business expansion and secured $40 million in term loans and working capital from leading banks. Drove a 9-fold growth in new business closures and top-line revenue for the CRO division over a five-year period.

Successfully executed a greenfield project, securing all statutory permissions and establishing facilities. Closed various business deals to set the company on its path.

Launched a $25M Greenfield Project and operationalized the new business venture 6 months ahead of schedule.